Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report sent to investors on Saturday. The firm issued a sell rating on the stock.

Bio-Path Stock Down 18.2 %

NASDAQ:BPTH opened at $0.14 on Friday. Bio-Path has a 1 year low of $0.12 and a 1 year high of $4.55. The stock’s 50 day simple moving average is $0.19 and its two-hundred day simple moving average is $0.66.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.